Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations

References

• American Cancer SocietyCancer Statistics Center2016 Available from: https://cancerstatisticscenter.cancer.org/?_ga=1.219304414.65199597.1475460858#/Accessed August 11, 2016
   Google Scholar
• TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• HurwitzMChemotherapy in prostate cancerCurr Oncol Rep201517104426216506
   PubMed Web of Science ®Google Scholar
• MitaACDenisLJRowinskyEKPhase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumorsClin Cancer Res200915272373019147780
   PubMed Web of Science ®Google Scholar
• de MorreeEvan SoestRAghaiAUnderstanding taxanes in prostate cancer; importance of intratumoral drug accumulationProstate2016761092793626997363
   PubMedGoogle Scholar
• de BonoJSOudardSOzgurogluMTROPIC InvestigatorsPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet201037697471147115420888992
   PubMed Web of Science ®Google Scholar
• HeidenreichAScholzHJRogenhoferSCabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programmeEur Urol201363697798223116658
   PubMed Web of Science ®Google Scholar
• BahlAMassonSMalikZFinal quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)BJU Int2015116688088725639506
   PubMed Web of Science ®Google Scholar
• HeidenreichABracardaSMasonMEuropean InvestigatorsSafety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programmeEur J Cancer20145061090109924485664
   PubMed Web of Science ®Google Scholar
• BonoJSDHardy-BessardA-CKimC-SPhase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D)J Clin Oncol2016345008
   Google Scholar
• FumoleauPTrigoJMIsambertNSémiondDGuptaSCamponeMPhase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumoursBMC Cancer201313146024099585
   PubMedGoogle Scholar
• CalvoOFParraEFPerez-ValderramaBWeekly cabazitaxel in “unfit” metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: preliminary results of CABASEM-SOGUG phase II trialJ Clin Oncol201533suppl 7 Abstract167
   Google Scholar
• van SoestRJde MorreeESKweldamCFTargeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancerEur Urol201567698198525484141
   PubMed Web of Science ®Google Scholar
• SellaASellaTPeerAActivity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancerClin Genitourin Cancer201412642843225066221
   PubMedGoogle Scholar
• PezaroCJOmlinAGAltavillaAActivity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agentsEur Urol201466345946524411987
   PubMedGoogle Scholar
• Al NakouziNLe MoulecSAlbigesLCabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapiesEur Urol201568222823524837187
   PubMed Web of Science ®Google Scholar
• SonpavdeGBhorMHennessyDSequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practicesClin Genitourin Cancer201513430931825743206
   PubMed Web of Science ®Google Scholar
• van SoestRJNieuweboerAJMde MorréeESDutch Uro-Oncology Study group (DUOS)The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancerEur J Cancer201551172562256926278646
   PubMed Web of Science ®Google Scholar
• AntonarakisESTagawaSTGallettiGTAXYNERGY InvestigatorsRandomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-naïve, metastatic, castration-resistant prostate cancerJ Clin Oncol Epub2017620
   Google Scholar
• WissingMDCoenenJLvan den BergPCAST: a retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxelInt J Cancer20151366E760E77225242736
   PubMed Web of Science ®Google Scholar
• CaffoOBriaEGiorgiUDOutcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: final analysis from a multicenter Italian studyJ Clin Oncol201735 Abstract5030
   PubMedGoogle Scholar
• DelanoyNAngelerguesAEfstathiouESequencing in metastatic castration-resistant prostate cancer (mCRPC): updated results of the FLAC International DatabaseJ Clin Oncol201735 Abstract267
   Google Scholar
• ThibaultCEymardJ-CHardy-BessardA-CEfficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC)J Clin Oncol201735 Abstract5033
   Google Scholar
• OudardSFizaziKSengeløvLCabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized Phase III trial—FIRSTANAJ Clin Oncol2017
   PubMedGoogle Scholar
• LevitanDCabazitaxel No Better Than Docetaxel in Metastatic CRPC2016 Available at: http://www.cancernetwork.com/asco-prostate-cancer/cabazitaxel-no-better-docetaxel-metastatic-crpcAccessed October 1, 2016
   Google Scholar
• FiaziKHotteSJSaadFFinal overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castrate resistant prostate cancerAnn Oncol2016276136
   PubMedGoogle Scholar
• ArmstrongAJHumeniukMSHealyPPhase Ib trial of cabazitaxel and tasquinimod in men with heavily pretreated metastatic castration resistant prostate cancer (mCRPC): the CATCH trialProstate201777438539527862097
   PubMed Web of Science ®Google Scholar
• MassardCMateoJLoriotYPhase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abirateroneAnn Oncol2017281909528039155
   PubMed Web of Science ®Google Scholar
• AparicioAXiaoLTapiaELNThe aggressive variant prostate carcinoma (AVPC) molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC)J Clin Oncol201736 Abstract5013
   Google Scholar
• MeiselAvon FeltenSVogtDRSevere neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TROPIC phase III trialEur J Cancer2016569310026829012
   PubMed Web of Science ®Google Scholar
• AntonarakisESLuCWangHAR-V7 and resistance to enzalutamide and abiraterone in prostate cancerN Engl J Med2014371111028103825184630
   PubMed Web of Science ®Google Scholar
• AntonarakisESLuCLuberBAndrogen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancerJAMA Oncol20151558259126181238
   PubMed Web of Science ®Google Scholar
• ChowdhurySBirtleAJBjartellAReal-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The Prostate Cancer RegistryJ Clin Oncol201735 Abstract5038
   Google Scholar
• Kellokumpu-LehtinenP-LMarttilaTJekunenAPBiweekly cabazitaxel as a safe treatment option for metastatic castration resistant prostate cancer (mCRPC) patients post-docetaxel: Final analysis of Prosty II trialJ Clin Oncol20163415_supple16523e16523
   Google Scholar